Corvus Pharmaceuticals Inc (CRVS)

Peripheral T-Cell Lymphoma, Not Otherwise Specified · registered primary completion 2027-11-01 · NCT06561048

Published 2026-09-02Market cap $1,191M7 sourced statements

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma · PHASE3 · n=150 · recruiting

Market

fact

No approved product carries Peripheral T-Cell Lymphoma, Not Otherwise Specified on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT06561048: randomized, open-label, 150 participants (estimated). Primary outcome: Progression-free survival.

Source: ClinicalTrials.gov record

Runway

fact

Cash of $215M against operating outflow of $14M per quarter gives roughly 15.7 quarters of runway, clearing the registered primary completion 4.7 quarters out by 11.0 quarters.

Source: 10-Q filed 2026-08-06

Share count and dilution

fact

84,120,944 shares outstanding against 98,149,121 if every outstanding option, warrant and convertible were exercised. In that case 14.3% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-06

Regulatory

fact

Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug, PRIME (EU). These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-06

Pipeline

fact

4 distinct molecules in 3 active company-sponsored trials; Soquelitinib accounts for 2 of them at Phase 2/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 19.7%.

Source: DEF 14A filed 2026-04-24

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.